PT  - JOURNAL ARTICLE
ED - BMJ Publishing Group Ltd
TI  - ▼Teriflunomide for multiple sclerosis
AID  - 10.1136/dtb.2014.7.0267
DP  - 2014 Jul 01
TA  - Drug and Therapeutics Bulletin
PG  - 81--84
VI  - 52
IP  - 7
4099  - http://dtb.bmj.com/content/52/7/81.short
4100  - http://dtb.bmj.com/content/52/7/81.full
SO  - Drug Ther Bull2014 Jul 01; 52
AB  - ▼Teriflunomide (Aubagio—Genzyme Therapeutics), the main metabolite of the disease-modifying anti-rheumatic drug leflunomide,1 is an immunomodulatory agent with anti-inflammatory properties.2 It is a new oral treatment licensed for adults with relapsing-remitting multiple sclerosis. Here we discuss the evidence for its effectiveness and safety, and consider its place in therapy.